Pandia Health Safety, Regulation & Compliance: An Independent Review

What Is Pandia Health and How Does It Operate?

Pandia Health is a U.S. Telehealth company founded in 2016. Its core services are online prescription of hormonal contraception and, more recently, menopause hormone therapy (MHT). The platform targets patients who want to avoid in-office visits to obtain or renew a contraceptive prescription.

Clinicians on the platform are licensed physicians. Consultations are primarily asynchronous: a patient fills out a structured health questionnaire, and a physician reviews it before approving or declining a prescription. Some states require a synchronous video or phone visit; Pandia Health is designed to comply with those state-specific requirements.

The Ryan Haight Act and Telehealth Prescribing Law

Any telehealth company prescribing controlled substances must comply with the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Oral contraceptives and most menopause hormone therapies are not DEA-controlled substances, so the Ryan Haight Act's in-person visit requirement does not directly apply to Pandia Health's core formulary. That distinction matters: it means Pandia Health can legally prescribe combined oral contraceptives (COCs), progestin-only pills, the patch, and vaginal rings via asynchronous intake alone, provided the prescribing physician holds a valid state license in the patient's state of residence.

State Licensure and Multi-State Coverage

Pandia Health maintains physician licensure across most U.S. States. Patients are required to attest their state of residence during sign-up; the platform routes the consultation to a physician licensed in that state. This is the correct legal framework. The Federation of State Medical Boards (FSMB) position statement on telemedicine, last updated in 2020, specifies that the standard of care in telehealth must equal the standard expected in an in-person encounter for the same clinical situation.

How Pandia Health Screens for Safety Before Prescribing

Safe prescribing of hormonal contraception requires ruling out contraindications. The WHO Medical Eligibility Criteria for Contraceptive Use (WHO MEC), 5th edition, classifies combined hormonal contraceptives (CHCs) as Category 4 (contraindicated) in patients with a history of venous thromboembolism (VTE), current ischemic heart disease, migraines with aura, or uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg) [1].

Intake Questionnaire Coverage

Pandia Health's patient intake form covers the major WHO MEC Category 3 and 4 contraindications, including migraine history (with or without aura), prior VTE, hypertension, liver disease, and smoking status in patients 35 years or older. Patients self-report their blood pressure. No in-person blood pressure measurement is required before the first prescription.

That self-report model is common across asynchronous telehealth prescribers, but it carries a documented limitation. A 2021 review in the American Journal of Obstetrics and Gynecology noted that hypertension is underdiagnosed and that patients in primary care settings often do not know their current blood pressure values [2]. Self-reported data in online forms may therefore miss WHO MEC Category 3 or 4 hypertension in a non-trivial proportion of users.

Physician Review of Intake Data

After the questionnaire is submitted, a licensed physician (not an algorithm alone) reviews the responses. If contradictory or high-risk answers appear, the physician can decline the prescription, request additional information, or recommend an in-person visit. This physician-in-the-loop model is consistent with ACOG Practice Bulletin No. 206 (2019), which states that "for most healthy women, a thorough medical history is sufficient to identify contraindications to hormonal contraceptive use" [3].

The ACOG bulletin supports the idea that a pelvic exam and blood pressure measurement are not required before prescribing hormonal contraceptives in low-risk patients. This provides a reasonable clinical basis for Pandia Health's asynchronous model.

Limitations of Asynchronous Screening

The model has real boundaries. No physical exam occurs. No laboratory work is ordered as a prerequisite. For patients with complex histories, diabetes, or possible metabolic conditions, a first prescription through an asynchronous platform may not catch clinically relevant details that an in-person provider would identify. Pandia Health's intake form asks about diabetes and liver disease, but it cannot replicate an HbA1c measurement or a liver enzyme panel.

FDA-Approved Products and Formulary Safety

All contraceptives Pandia Health prescribes are FDA-approved products. The platform does not compound hormonal contraceptives or dispense unapproved ingredients for its contraception service. This is a meaningful safety boundary: compounded hormonal products lack the efficacy and safety data package that approved drugs carry.

Combined Oral Contraceptives

COCs on the Pandia Health formulary include products containing ethinyl estradiol paired with levonorgestrel, norethindrone, or desogestrel, among others. The FDA-approved labeling for COCs consistently warns about VTE risk. According to FDA prescribing information for levonorgestrel/ethinyl estradiol tablets, the absolute risk of VTE in COC users is approximately 3 to 9 per 10,000 woman-years, compared with 1 to 5 per 10,000 in non-pregnant, non-COC users [4].

The clinical reality is that this risk is low in absolute terms for healthy, non-smoking women under 35 with no personal or family history of clotting disorders. The risk-benefit calculation shifts meaningfully in patients with the WHO MEC Category 3 or 4 conditions listed above, which is why accurate contraindication screening is the fulcrum of safety in this model.

Progestin-Only Pills

For patients who cannot use estrogen-containing products (those who smoke over 35, have migraines with aura, or have a prior VTE), progestin-only pills (POPs) such as norethindrone are an appropriate alternative. POPs do not carry the same VTE risk profile as COCs [5]. Pandia Health prescribes POPs, which means a prescriber who correctly identifies a COC contraindication has an alternative to offer rather than simply declining to help.

Menopause Hormone Therapy

Pandia Health's menopause service prescribes FDA-approved MHT formulations. The evidence base for MHT is anchored in the Women's Health Initiative (WHI), which originally reported increased risks of breast cancer, VTE, and stroke with oral combined estrogen-progestin therapy in older postmenopausal women. Subsequent re-analysis and the KEEPS trial (Kronos Early Estrogen Prevention Study) refined those findings: the North American Menopause Society (NAMS) 2022 position statement concludes that for women under 60 years of age or within 10 years of menopause onset, the benefits of MHT generally outweigh the risks for bothersome vasomotor symptoms in the absence of contraindications [6].

A critical prescribing consideration for asynchronous MHT is identifying patients who fall outside the "timing hypothesis" favorable window, i.e., those more than 10 years past menopause or over age 60. Pandia Health's intake form captures date of last menstrual period and age, which enables this calculation. Whether the physician review consistently applies the NAMS 10-year rule in every case is not independently auditable from outside the platform.

Regulatory Standing and Compliance Posture

No Public FDA Enforcement Actions

As of the review date, the FDA's public database of warning letters and enforcement actions does not list Pandia Health as a recipient of a warning letter or import alert. This absence is not a guarantee of compliance perfection, but it is a relevant baseline fact.

State Medical Board Oversight

Physician prescribers at Pandia Health are licensed by state medical boards and are subject to those boards' disciplinary processes. A patient who experiences harm from a prescription may file a complaint with the relevant state medical board. This is the same accountability structure that governs any licensed physician.

DEA Registration and Controlled Substances

Pandia Health does not prescribe Schedule II-V controlled substances as part of its core formulary. Contraceptives and most menopause therapies do not require DEA registration to prescribe. This simplifies the compliance picture compared to telehealth platforms that prescribe stimulants or opioids.

Pharmacy Partner Verification

Pandia Health works with licensed U.S. Pharmacies to fulfill prescriptions. Patients can direct a prescription to a local pharmacy or use the mail delivery option. The dispensing pharmacies are state-licensed, which means they operate under the same rules as any retail pharmacy regarding dispensing accuracy and drug storage.

How Pandia Health Compares to Alternatives

Telehealth Competitors: Nurx, The Pill Club, Hey Jane

Nurx, The Pill Club (now Favor), and Hey Jane operate similar asynchronous prescribing models for contraception. All rely on patient self-reported intake questionnaires and physician review. The key differentiators across these platforms are formulary breadth, pricing transparency, turnaround time, and whether a synchronous visit option exists.

A 2019 study in JAMA Internal Medicine (N=4,900 intake records reviewed by mystery shoppers) found that direct-to-consumer birth control services varied significantly in how thoroughly they screened for WHO MEC Category 4 contraindications. Specifically, 22% of platforms in that sample failed to ask about migraine with aura before prescribing COCs [7]. Pandia Health's intake form does ask about migraine with aura, which puts it above that lower bound, though independent real-time auditing of current intake forms is beyond the scope of this review.

In-Person Primary Care or Gynecology

An in-person provider offers blood pressure measurement, clinical judgment during a physical exam, and the ability to order labs. For patients with complex comorbidities or a prior adverse event on hormonal contraceptives, an in-person prescriber is the better-matched level of care. For healthy, low-risk patients seeking a routine prescription renewal, ACOG's own guidance (Practice Bulletin 206) supports the adequacy of a thorough medical history alone, which is what telehealth platforms deliver.

Cost Comparison

Pandia Health operates on a cash-pay model. Generic COC costs through mail-order telehealth platforms typically range from $0 to $50 per month depending on the specific product and whether the patient uses insurance at a retail pharmacy instead. The Title X family planning program provides free or low-cost contraception to eligible patients at federally qualified health centers [8]. Patients for whom cost is the primary barrier may find Title X-funded clinics a more affordable option than any cash-pay telehealth service.

Known Risks and Patient Safety Considerations

VTE Risk Disclosure

Pandia Health's website and prescription materials reference VTE risk as required by FDA-mandated labeling. The incidence of VTE in healthy COC users is low in absolute terms. To put it concretely, a 2014 BMJ study (N=1,626,158 women) found that levonorgestrel-containing pills were associated with a VTE rate of approximately 5.6 per 10,000 woman-years, while desogestrel-containing pills showed approximately 9.8 per 10,000 woman-years [9]. The baseline risk in non-pregnant women not using hormonal contraception is approximately 2 per 10,000 woman-years.

Absence of Blood Pressure Measurement

This is the most frequently cited safety limitation of asynchronous contraceptive telehealth. Uncontrolled hypertension is a WHO MEC Category 3 or 4 contraindication for CHCs. Without a measured blood pressure, a prescriber relies entirely on the patient's self-report. Patients who do not know they are hypertensive cannot self-report it. The American Heart Association's 2017 guidelines redefined hypertension as >130/80 mmHg, which means the pool of patients with unrecognized hypertension in the U.S. Is substantial [10].

Pandia Health mitigates this partially by asking patients if they have ever been told by a provider that they have high blood pressure. This is an imperfect but widely used proxy in telehealth. Some platforms additionally ask patients to take a blood pressure reading at a pharmacy kiosk before prescribing; Pandia Health does not appear to require this as a universal prerequisite.

No Emergency Contraception Prescribing Gap

Pandia Health does not fill emergency contraception prescriptions on demand in most cases, given the time-sensitive nature of that product. Plan B and generic levonorgestrel 1.5 mg tablets are available over the counter without a prescription in the U.S. [11], so this is not a practical gap for most patients. Ella (ulipristal acetate 30 mg) does require a prescription; whether Pandia Health can fulfill that prescription within the 120-hour effective window via asynchronous consult depends on turnaround time.

Clinical Guidelines Pandia Health Should Align With

The two most authoritative documents governing hormonal contraceptive prescribing in the U.S. Are:

1. ACOG Practice Bulletin No. 206 (2019): Recommends against requiring a pelvic exam before initiating COCs, supports self-reported blood pressure for low-risk patients, and endorses a 12-month supply prescription to improve continuation rates [3].

2. CDC U.S. Medical Eligibility Criteria for Contraceptive Use (2016, updated 2020): The U.S. Adaptation of WHO MEC. Classifies contraindications using the same 1-4 scale. Available at the CDC website and is the standard reference for U.S. Prescribers [12].

For MHT, the NAMS 2022 Hormone Therapy Position Statement is the governing reference [6]. It supports prescribing MHT for symptomatic women under 60 or within 10 years of menopause with a thorough medical and family history review.

Pandia Health's prescribing model is structurally consistent with both ACOG Practice Bulletin 206 and CDC MEC for a low-risk patient population. The platform's limitations are most apparent in edge cases: patients with unrecognized cardiovascular risk factors, complex family histories, or who are more than 10 years postmenopausal.

Is Pandia Health Legitimate?

Yes, by the standard legal and regulatory definitions. Pandia Health employs licensed physicians, prescribes only FDA-approved medications, works with licensed pharmacies, and operates under state telehealth prescribing laws. It has no public FDA enforcement history.

"Legitimate" does not mean "appropriate for every patient." The correct question is not whether the platform is licensed (it is) but whether the level of care it provides is the right match for a specific patient's clinical complexity. A 24-year-old non-smoker with no personal or family history of clotting disorders seeking a COC renewal is well-served by an asynchronous telehealth model. A 52-year-old with a first-degree relative with breast cancer seeking MHT benefits from a more detailed synchronous consultation.

What Pandia Health Prescribes: Full Scope

• Combined oral contraceptives (multiple generic and brand formulations)
• Progestin-only pills (norethindrone)
• Contraceptive patch (norelgestromin/ethinyl estradiol transdermal system)
• Vaginal ring (etonogestrel/ethinyl estradiol)
• Menopause hormone therapy (estrogen and combined estrogen-progestin regimens, FDA-approved products)

The platform does not prescribe intrauterine devices (IUDs), contraceptive implants (Nexplanon), or injectable contraceptives (Depo-Provera), as these require an in-person procedural visit. Patients seeking LARC (long-acting reversible contraception) must see an in-person provider.